Form 4: Athira Pharma Director James A. Johnson Acquires Stock Options
SEC Form 4 Filing
Director James A. Johnson acquired stock options in Athira Pharma, Inc. on May 24, 2024.
Summary
- On May 24, 2024, James A. Johnson, a director of Athira Pharma, Inc., acquired 20,900 stock options at an exercise price of $2.64.
- These options vest on the earlier of May 24, 2025, or the day before the next annual meeting of the Issuer's stockholders after May 24, 2024.
- Following this transaction, Johnson directly owns 20,900 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.
Positives
- The acquisition of stock options by a director may signal confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.
Stakeholder Impact
- The transaction could be viewed positively by shareholders as it indicates a director's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 05/24/2024 | Date of transaction: James A. Johnson acquired stock options. |
| 05/24/2025 | Earliest vesting date for the acquired stock options. |
| 05/23/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.